Biggest News Aggregation in the World
📰 Eceptor News

Page 41 - Eceptor News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Eceptor. Real-time updates on events, politics, business and more.

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

- Oral presentation to describe distinct receptor binding and mechanistic characteristics of VRDN-001, Company’s lead pipeline candidate in its thyroid eye disease program - - Poster... | June 13, 2023
United States Viridian Therapeutics Inc Receptor In Development Meeting Of The Endocrine Society Company Annual Report On Form Exchange Commission

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.
United States District Of Columbia Margaret Meg Haney Francesr Levin Vincenzo Piazza Daelis Farma

Single virus binds to a single receptor, study reveals

In Europe, the pandemic triggered in 2020 by the SARS-CoV-2 coronavirus is now largely under control. But why this virus is able to spread so efficiently remains unclear. A team of researchers led by Dr. Simone Backes, Dr. Gerti Beliu and Prof. Dr. Markus Sauer of the Julius Maximilians University of Würzburg (JMU) has now shown in a publication in "Angewandte Chemie" that some previous assumptions need to be reconsidered.
Megan Craig Markus Sauer Angewandte Chemie Simone Backes Julius Maximilians University Rudolf Virchow Center

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.
Sanchari Sinha Dutta Greater Combined Reductions Body Weight Loss Orally Administered Semaglutide Versus Image Credit Peptide Innovation

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science